Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LRIT1 (Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1) is a transmembrane synaptic adhesion-like protein specifically enriched at retinal cone photoreceptor synapses. It contains leucine-rich repeat motifs, immunoglobulin-like domains, fibronectin type III domains, and a transmembrane region anchoring it at the synapse. LRIT1 is critical for normal cone synaptic communication, enabling dynamic scaling of photoreceptor response to varying light conditions and maintaining visual acuity. LRIT1 forms a molecular complex with the glutamate receptor mGluR6 on ON-bipolar cells and the photoreceptor scaffold protein Frmpd2, regulating synaptic architecture and functional connectivity. Knockout or deficiency of LRIT1 in mice leads to abnormal synaptic signaling and impaired adaptation in vision, indicating its essential role in retinal function, but it is not a direct therapeutic drug target.
None known (no current drugs or agents act mechanistically through LRIT1)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 (LRIT1).